Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Intronic DNA variants in EZH2 and GATA2 predict treatment-free remission in chronic myeloid leukemia patients from the destiny trial

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShaun PattersonRCRichard E. ClarkHJHeather G. Jørgensen

Discussion

Loading...

Member takes

Overview

Contingency analysis shows intronic variants in EZH2 and GATA2 predict treatment-free remission in chronic myeloid leukemia patients, suggesting novel biomarkers for TKI discontinuation.

Key Points

  • Patients with intronic variants in ezh2 or gata2 had significantly improved treatment-free remission rates.
  • Using logistic regression, researchers predict molecular recurrence linked to specific genetic variants in CML patients.
  • Participants underwent next generation sequencing to analyze variants related to clonal hematopoiesis and treatment response.
  • Findings suggest that targeted sequencing can assist in risk stratification for CML patients considering TKI discontinuation.

Cite This Study

Patterson et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3e9https://doi.org/10.1182/blood-2025-5558
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of predictive protein signatures of treatment-free remission in patients with chronic myeloid leukaemia2025
  2. 2BCR::ABL1 evaluation in bone marrow is no more predictive of TFR success than from peripheral blood2025
  3. 3Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response2025
  4. 4Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis2025
  5. 5Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia2025